Overview

PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the concentration of four different metabolites in the tumor, in adjacent mucosa and in plasma in patients with colon cancer receiving two different doses of Modufolin (arfolitixorin) and Levoleucovorin (Isovorin®), respectively (60 and 200 mg/m2).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Isofol Medical AB

Treatments:

Leucovorin
Levoleucovorin
Tetrahydrofolates